An Early Phase 1 interventional study of ultrasound-guided stellate ganglion block in Traumatic Brain Injury, sponsored by Sohag University. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.
Sponsored by Sohag University · Early Phase 1, Interventional, and Treatment
the study is designed to perform an intervention for enhancement of cerebral blood flow in patients with traumatic brain injury showing vasospasm through transcranial doppler
2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.
This study's planned enrollment of 60 is above the median of 48 across 1,331 interventional studies indexed under Brain Injuries.
Browse Brain Injuries studies →Sohag University is the lead sponsor of 1,183 studies on the registry; 612 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Hemodynamic instability (mean ABP less than 70 mmHg)
stellate ganglion will have ultrasound-guided block via bupivacaine for sympathectomy and enhancement of cerebral blood flow
Procedure: ultrasound-guided stellate ganglion block
intravenous nimodipine will be given for enhancement of cerebral blood flow
Procedure: ultrasound-guided stellate ganglion block
under aseptic conditions, using the ultrasound guidance, bilateral stellate ganglion block will be done using bupivacaine and betamethasone mixture, 8 ml volume will be given for each side
enhancement of cerebral blood flow
increased blood flow through middle cerebral artery and basilar artery measured by transcranial doppler ultraound
Time frame: one week
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sohag University